Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217117 | 0.97 | MAPT (0.53) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217131 | 0.91 | PTPN11 (0.55) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217109 | 0.89 | NAMPT (0.47) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217419 | 0.89 | LMNA (0.49) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217367 | 0.89 | LMNA (0.49) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217265 | 0.88 | PTPN11 (0.56) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217103 | 0.87 | LMNA (0.49) | LMNAMAPTGAASMN1; SMN2HTT | |
| Formic Acid SCHEMBL23217369 | 0.86 | PTPN11 (0.54) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217298 | 0.83 | MAPT (0.46) | LMNAMAPTGAASMN1; SMN2HTT | |
| SCHEMBL23217100 | 0.80 | MAPT (0.70) | LMNAMAPTGAASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | LMNA 512/4885MAPT 4754/4885GAA 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.